The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

We investigated the effects of chronic treatment with the CB1 receptor antagonist rimonabant (10 mg/kg/day p.o. for 10 weeks) in mice with established obesity (5‐month high‐fat diet). Untreated obese mice showed a weight gain of 46% (45.0 ± 0.6 g vs. 30.8 ± 0.5 g) compared with age‐matched animals f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2005-01, Vol.7 (1), p.65-72
Hauptverfasser:	Poirier, B., Bidouard, J.-P., Cadrouvele, C., Marniquet, X., Staels, B., O'Connor, S. E., Janiak, P., Herbert, J.-M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adiponectin Animals Anti-Obesity Agents - therapeutic use Blood Glucose - analysis body weight CB1 receptor antagonist Cholesterol - blood Cholesterol, HDL - blood food intake glucose insulin Insulin - blood Intercellular Signaling Peptides and Proteins - blood Leptin - blood Lipids - blood lipoproteins Male Mice Mice, Inbred C57BL obesity Obesity - blood Obesity - drug therapy Piperidines - therapeutic use Pyrazoles - therapeutic use rimonabant
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We investigated the effects of chronic treatment with the CB1 receptor antagonist rimonabant (10 mg/kg/day p.o. for 10 weeks) in mice with established obesity (5‐month high‐fat diet). Untreated obese mice showed a weight gain of 46% (45.0 ± 0.6 g vs. 30.8 ± 0.5 g) compared with age‐matched animals fed a standard diet. Rimonabant treatment, commencing after 5‐month high‐fat diet, produced a marked and sustained decrease in body weight (34.5 ± 0.8 g vs. 47.2 ± 0.5 g in the high‐fat vehicle group, p
ISSN:	1462-8902 1463-1326
DOI:	10.1111/j.1463-1326.2004.00374.x